Biophytis: A Promising Biotech Player in the Age-Related Disease Market

Biophytis SA, a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, recently announced its participation in the Biomed Forum investor conference. This annual event, organized by All Invest Securities, brings together biotech and medtech companies with institutional investors, providing an opportunity for Biophytis to engage with French and European investors, share updates on its latest developments, and outline its outlook for 2025.

Biophytis' lead drug candidate, BIO101 (20-hydroxyecdysone), is a small molecule in development for multiple age-related diseases, including muscular diseases (sarcopenia and Duchenne muscular dystrophy), respiratory diseases (COVID-19), and metabolic disorders (obesity). The company's focus on age-related diseases positions it in a competitive landscape where investors seek innovative solutions to address the growing prevalence of these conditions.

BIO101's versatility and potential in multiple therapeutic areas offer several advantages to investors:

1. Broad market potential: By targeting multiple age-related diseases, BIO101 opens up a wide range of potential markets, reducing the risk associated with relying on a single indication.
2. Clinical progress: Biophytis has made significant progress in clinical trials for BIO101, with Phase 2-3 trials completed for COVID-19 and Phase 3 ready to start for sarcopenia. This demonstrates the drug's potential and the company's ability to advance its pipeline.
3. Strong safety profile: BIO101 has shown a very good safety profile in clinical trials, with no significant differences in adverse events, serious adverse events, or safety parameters between treatment groups and the placebo group.
4. Intellectual property: Biophytis has a strong intellectual property portfolio, with multiple patents filed and granted for BIO101, protecting its lead drug candidate and providing a competitive advantage.
5. Experienced management team: The company's management team has a proven track record in the biotechnology industry, with expertise in drug development, clinical trials, and regulatory affairs, which increases the likelihood of success.
6. Potential for partnerships: Biophytis' focus on age-related diseases and its lead drug candidate's versatility make it an attractive partner for other biotechnology and pharmaceutical companies, as well as for investors seeking exposure to the growing market for age-related disease treatments.

By participating in the Biomed Forum, Biophytis aims to strengthen relationships with investors, update them on recent developments, attract new investors, and gather feedback and insights. This event provides an opportunity for the company to showcase its pipeline, share its vision for the future, and engage with the investment community.



In conclusion, Biophytis' participation in the Biomed Forum investor conference highlights the company's commitment to engaging with investors and sharing its progress in the development of BIO101 for age-related diseases. With its broad market potential, clinical progress, strong safety profile, intellectual property, experienced management team, and potential for partnerships, Biophytis offers an attractive investment opportunity in the competitive biotechnology sector. As the company continues to advance its pipeline and explore strategic partnerships, investors should keep a close eye on Biophytis' progress in the age-related disease market.